peptide loaded dendritic cell vaccine

This autologous dendritic cell vaccine is a personalized biologic immunotherapy developed by the National Cancer Institute (NCI) for the treatment of various metastatic malignancies, including melanoma and epithelial cancers such as gastrointestinal, breast, ovarian, and pancreatic cancers. The vaccine is manufactured by identifying patient-specific tumor mutations (neoantigens) through exome and RNA sequencing of the patient's resected tumor tissue. Patient-derived dendritic cells are harvested via apheresis and pulsed with long peptides corresponding to these identified immunogenic neoantigens. Once administered back to the patient through both intravenous and subcutaneous routes, the vaccine is designed to present these tumor-specific neoantigens to the immune system, thereby stimulating a targeted T-cell response against the cancer cells expressing those specific mutations.

Other names

Autologous dendritic cell vaccine pulsed with personalized neoantigen peptidesNeoantigen-based dendritic cell vaccinePeptide loaded dendritic cell vaccine